Chemical Namevismodegib
Dosage FormCapsule (oral; 150 mg)
Drug ClassInhibitors
Approval Year2012


  • For the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation
Last updated on 4/19/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Erivedge (vismodegib) Prescribing Information.2012Genentech USA, Inc., South San Francisco, CA
Document TitleYearSource
Guidelines of care for the management of basal cell carcinoma.2018American Academy of Dermatology
Basal cell skin cancer, version 1.2016.2016Journal of the National Comprehensive Cancer Network